

Horizon Pharma plc  
Form 4  
March 02, 2017

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Carey Robert

(Last) (First) (Middle)

C/O HORIZON PHARMA  
PLC, CONNAUGHT HOUSE, 1ST  
FL, 1 BURLINGTON RD

(Street)

DUBLIN, L2 4

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
Horizon Pharma plc [HZNP]

3. Date of Earliest Transaction  
(Month/Day/Year)  
02/28/2017

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
EVP, Chief Business Officer

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)		
				Code	V	Amount				(A) or (D)	Price
Ordinary Shares	02/28/2017		X			6,913	A	\$ 4.308	127,216 <sup>(1)</sup>	I	By Robert F. Carey III Trust dated 4/24/2001
Ordinary Shares	02/28/2017		S <sup>(2)</sup>			1,808	D	\$ 16.48	125,408	I	By Robert F. Carey III Trust dated 4/24/2001
Ordinary Shares	03/01/2017		S			30,000	D	\$ 16	95,408	I	By Robert F. Carey III Trust dated

4/24/2001

Ordinary Shares 600 <sup>(3)</sup> D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Warrant to Purchase Ordinary Shares (Right to Buy)	\$ 4.308	02/28/2017		X	6,913	03/02/2012 03/02/2017	Ordinary Shares	6,913

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director 10% Owner Officer Other

Carey Robert  
C/O HORIZON PHARMA PLC  
CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD  
DUBLIN, L2 4

EVP, Chief Business Officer

## Signatures

/s/ Paul W. Hoelscher, Attorney-in-Fact 03/02/2017

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes 38,242 shares which were transferred from the Reporting Person to the Trust on January 11, 2017.

Exercise of a warrant to purchase 6,913 ordinary shares of the Issuer for \$4.308 per share. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 1,808 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 5,105 shares. The warrant was scheduled to expire on March 2, 2017.

On June 1, 2016, 1,173 ordinary shares of the Issuer were acquired by the reporting person pursuant to an employee stock purchase program. The number of Issuer shares previously reported as beneficially owned by the reporting person was incorrectly over reported on a prior Form 4 by 573 shares of the Issuer's common stock, and has been corrected with this filing.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.